Search results for "anticoagulation"

showing 10 items of 45 documents

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with…

2018

Summary Venous thromboembolism (VTE)‐BLEED, a decision tool for predicting major bleeding during chronic anticoagulation for VTE has not yet been validated in practice‐based conditions. We calculated the prognostic indices of VTE‐BLEED for major bleeding after day 30 and day 90, as well as for recurrent VTE and all‐cause mortality, in 4457 patients enrolled in the international, prospective XALIA study. The median at‐risk time was 190 days (interquartile range 106–360). The crude hazard ratio (HR) for major bleeding after day 30 was 2·6 [95% confidence interval (CI) 1·3–5·2] and the treatment‐adjusted HR was 2·3 (95% CI 1·1–4·5) for VTE‐BLEED high (versus low) risk patients: the correspondi…

AdultMalemedicine.medical_specialtyvenous thromboembolismHemorrhage030204 cardiovascular system & hematologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInterquartile rangePredictive Value of TestsInternal medicinemedicineanticoagulation therapy; bleeding; prediction; rivaroxaban; venous thromboembolism; HematologyHumans030212 general & internal medicinecardiovascular diseasesProspective StudiesAdverse effectrivaroxabanRivaroxabananticoagulation therapybusiness.industryIncidence (epidemiology)Platelets Haemostasis and ThrombosisHazard ratioHematologypredictionBleedMiddle Agedequipment and suppliesbleedingConfidence intervalddc:Survival RateCohortFemalebusinessmedicine.drugResearch Paper
researchProduct

CANCER AS A PREDICTOR FOR INCREASED PERIPROCEDURAL BLEEDING DURING SURGERY OR PLATELET-INDUCED CHEMOTHERAPY IN CHRONICALLY ANTICOAGULATED PATIENTS

2012

Anticoagulation bleedingSettore MED/15 - Malattie Del Sangue
researchProduct

Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome

2008

Experimental antiphospholipid syndrome (eAPS) induced by immunization with beta(2)-glycoprotein I (beta(2)-GPI) causes behavioral hyperactivity. We assessed the role of thrombotic and inflammatory perivascular factors and standard APS therapies for CNS manifestations. Groups of mice (n=10 per group) were immunized once with beta(2)-GPI (eAPS) or adjuvant (controls) and treated daily from 1 month after immunization with either sham injections, aspirin (1.2 mg/kg) or enoxaparin (1 mg/kg) for 3 months. Serum antiphospholipid antibodies (aPL) and brain levels of tissue necrosis factor-alpha (TNF-alpha) and prostaglandin E (PGE) were then measured by ELISA and thrombin inhibitors by immunoblot. …

Central Nervous Systemmedicine.medical_treatmentEnzyme-Linked Immunosorbent AssayInflammationPharmacologylcsh:RC321-571AnticoagulationMiceFibrinolytic AgentsAntiphospholipid syndromeAnimalsMedicineBeta 2-Glycoprotein IAlprostadilEnoxaparinlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryPhospholipidsInflammationBehaviorAnalysis of VarianceMice Inbred BALB CAspirinAspirinBehavior AnimalTumor Necrosis Factor-alphabusiness.industryThrombosisAntiphospholipid Syndromemedicine.diseaseThrombosisAnimal modelsDisease Models AnimalNeurologybeta 2-Glycoprotein IImmunologyExploratory BehaviorFemaleTumor necrosis factor alphamedicine.symptombusinessDiscovery and development of direct thrombin inhibitorsProstaglandin Emedicine.drugNeurobiology of Disease
researchProduct

Impacto pronóstico a largo plazo de la anticoagulación en pacientes en hemodiálisis con fibrilación auricular

2018

Resumen: Introducción y objetivos: La evidencia de la eficacia y seguridad de la anticoagulación oral con dicumarínicos en pacientes en hemodiálisis con fibrilación auricular (FA) es controvertida. El objetivo de nuestro estudio es evaluar las implicaciones a nivel pronóstico a largo plazo de la anticoagulación con dicumarínicos en una cohorte de pacientes con FA no valvular en programa de hemodiálisis debido a insuficiencia renal terminal. Métodos: Estudio observacional retrospectivo con inclusión consecutiva de 74 pacientes en hemodiálisis con FA. El periodo de inclusión fue de enero de 2005 a octubre de 2016. Las variables principales fueron mortalidad por todas las causas, reingresos no…

Gynecologymedicine.medical_specialtyHemodiálisisbusiness.industrymedicine.medical_treatmentAnticoagulación030232 urology & nephrologyAtrial fibrillation030204 cardiovascular system & hematologylcsh:Diseases of the genitourinary system. Urologylcsh:RC870-923medicine.diseaseAtrial fibrillationFibrilación auricular03 medical and health sciencesAnticoagulation0302 clinical medicineNephrologyHemodialysisMedicineEnfermeríaHemodialysisbusiness
researchProduct

The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implicat…

2022

Peripheral artery disease (PAD) is a clinical manifestation of atherosclerotic disease with a large-scale impact on the economy and global health. Despite the role played by platelets in the process of atherogenesis being well recognized, evidence has been increasing on the contribution of the coagulation system to the atherosclerosis formation and PAD development, with important repercussions for the therapeutic approach. Histopathological analysis and some clinical studies conducted on atherosclerotic plaques testify to the existence of different types of plaques. Likely, the role of coagulation in each specific type of plaque can be an important determinant in the histopathological compo…

Inorganic Chemistryanticoagulation atherosclerosis coagulation peripheral artery diseaseOrganic ChemistryGeneral MedicinePhysical and Theoretical ChemistryMolecular BiologySpectroscopyCatalysisComputer Science ApplicationsInternational Journal of Molecular Sciences
researchProduct

Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population‐Based Gutenberg Health Study

2018

Background Preclinical data have indicated a link between use of vitamin K antagonists ( VKA ) and detrimental effects on vascular structure and function. The objective of the present study was to determine the relationship between VKA intake and different phenotypes of subclinical cardiovascular disease in the population. Methods and Results Clinical and laboratory data, as well as medical–technical examinations were assessed from 15 010 individuals aged 35 to 74 years during a highly standardized 5‐hour visit at the study center of the population‐based Gutenberg Health Study. In total, the study sample comprised 287 VKA users and 14 564 VKA nonusers. Multivariable analysis revealed an in…

Male0301 basic medicineEpidemiologyPROGRESSION030204 cardiovascular system & hematologyVitamin kCarotid Intima-Media ThicknessTHERAPYGastroenterologyAdrenomedullin0302 clinical medicineRisk Factorscardiovascular diseaseGermanyAtrial FibrillationNatriuretic Peptide BrainMatrix gla proteinOriginal ResearchVenous Thrombosisoral anticoagulationRISKbiologyMiddle AgedStrokevitamin K antagonistsC-Reactive ProteinCardiovascular DiseasesFemaleCardiology and Cardiovascular MedicineAtrial Natriuretic Factormedicine.drugAdultmedicine.medical_specialtyPopulation basedMATRIX GLA-PROTEINWARFARIN03 medical and health sciencesVascular StiffnessInternal medicineORAL ANTICOAGULANTmedicineHumansAnkle Brachial IndexVascular structureProtein PrecursorsAgedInflammationVascular diseasebusiness.industryWarfarinAnticoagulantsFibrinogenStroke Volumepharmacogenomic variantsARTERIALmedicine.diseasePreclinical dataPeptide FragmentsCALCIFICATION030104 developmental biologyAsymptomatic DiseasesPhenprocoumonbiology.proteinPulmonary EmbolismbusinessCalcificationJournal of the American Heart Association
researchProduct

Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review an…

2018

Abstract Aims Patients with acute pulmonary embolism (PE) classified as low risk by the Pulmonary Embolism Severity Index (PESI), its simplified version (sPESI), or the Hestia criteria may be considered for early discharge. We investigated whether the presence of right ventricular (RV) dysfunction may aggravate the early prognosis of these patients. Methods and results We did a systematic review and meta-analysis of studies including low-risk patients with acute PE to investigate the prognostic value of RV dysfunction. Diagnosis of RV dysfunction was based on echocardiography or computed tomography pulmonary angiography. In addition, we investigated the prognostic value of elevated troponin…

MaleComputed Tomography AngiographyVentricular Dysfunction Right030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineNatriuretic peptidePulmonary angiographyHospital MortalityRight ventricular dysfunctionAged 80 and overbiologyMortality rateHome treatmentMiddle AgedPrognosisTroponinPulmonary embolismEchocardiographyMeta-analysisAcute DiseaseCardiologyFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtymedicine.drug_classFast Track Clinical ResearchRisk Assessment03 medical and health sciencesAnticoagulationInternal medicinemedicineHumansMortalityNatriuretic PeptidesRisk stratificationAgedbusiness.industryPulmonary embolismAnticoagulants030229 sport sciencesOdds ratiomedicine.diseaseTroponinConfidence intervalEditor's Choicebiology.proteinbusinessBiomarkersEuropean Heart Journal
researchProduct

Regional anticoagulation with heparin of an extracorporeal CO2 removal circuit: a case report

2019

Abstract Background Extracorporeal carbon dioxide removal is an increasingly used respiratory support technique. As is true of all extracorporeal techniques, extracorporeal carbon dioxide removal needs proper anticoagulation. We report a case of a patient at risk of bleeding complications who was treated with extracorporeal carbon dioxide removal and anticoagulated with a regional technique. Case presentation A 56-year-old Caucasian man with a history of chronic obstructive pulmonary disease exacerbation required extracorporeal carbon dioxide removal for severe hypercapnia and acidosis despite mechanical ventilation. The extracorporeal circuit was anticoagulated using a regional heparin tec…

MaleExtracorporeal CirculationLow platelet countExacerbationmedicine.medical_treatment2lcsh:MedicineCase Report030204 cardiovascular system & hematologyExtracorporealExtracorporeal carbon dioxide removal03 medical and health sciencesContinuous venovenous filtrationPulmonary Disease Chronic Obstructive0302 clinical medicineExtracorporeal CO 2 removalExtracorporeal Membrane OxygenationmedicineHeparin regional anticoagulationHumansAcidosisMechanical ventilationbusiness.industryHeparinMedicine (all)removallcsh:RAnticoagulantsExtracorporeal COGeneral MedicineHeparinExtracorporeal CO2 removalCarbon DioxideMiddle AgedRespiration ArtificialTreatment Outcome030220 oncology & carcinogenesisAnesthesiaDisease Progressionmedicine.symptomContinuous venovenous filtration; Extracorporeal CO ; 2; removal ; Heparin regional anticoagulationbusinessHypercapniamedicine.drugJournal of Medical Case Reports
researchProduct

Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism

2017

Essentials The long-term risk of recurrence and death after distal deep vein thrombosis (DVT) is uncertain. We included subjects with first proximal or isolated distal DVT (IDDVT) and no pulmonary embolism. The risk of symptomatic and asymptomatic recurrence is lower after IDDVT (vs. proximal). IDDVT may be associated with a lower long-term risk of death, especially after unprovoked DVT. SummaryBackground A few studies have focused on the risk of recurrence after first acute isolated distal deep vein thrombosis (IDDVT) compared with proximal DVT (PDVT), whereas the incremental risk of death has never been explored beyond the first 3 years after acute event. Methods Our single-center cohort …

Malemedicine.medical_specialtyDeep veinKaplan-Meier Estimate030204 cardiovascular system & hematologyLower riskGastroenterologyAsymptomaticVeinsanticoagulation; death; distal deep vein thrombosis; pulmonary embolism; venous thromboembolism; Hematology03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsdeathInternal medicinemedicineHumans030212 general & internal medicineanticoagulationAgedVenous Thrombosisbusiness.industryMortality rateHazard ratioVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismVenous thrombosisTreatment Outcomemedicine.anatomical_structureFemaledistal deep vein thrombosismedicine.symptomPulmonary EmbolismbusinessFollow-Up StudiesJournal of Thrombosis and Haemostasis
researchProduct

Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation

2008

Aims: To gain insight in the prognosis and treatment of atrial fibrillation (AF) patients during 1-year follow-up in the Euro Heart Survey (EHS) on AF. Methods and results: The EHS enrolled 5333 AF patients in 2003-2004. One-year follow-up data were available for 80%. Of first detected AF patients, 46% did not have a recurrence during 1 year, paroxysmal AF largely remained paroxysmal AF (80%), and 30% of persistent AF progressed to permanent AF. Many treatment changes occurred since baseline. Oral anticoagulation was started in 19% and discontinued in 16% of all patients. Of patients initially on rhythm control 27% did not receive rhythm control during follow-up, whereas 15% of patients ini…

Malemedicine.medical_specialtyRate controlHeart DiseasesHeart diseasePrognosiHemorrhageRisk AssessmentAnticoagulationElectrocardiographyInternal medicineAtrial FibrillationHumansMedicineSinus rhythmProspective StudiesMortalityProspective cohort studyStrokeSurvival rateAgedProgressionmedicine.diagnostic_testbusiness.industryAnticoagulantAnticoagulantsAtrial fibrillationPrognosismedicine.diseaseManagementStrokeSurvival RateProspective StudieHeart DiseaseTreatment OutcomeHeart failureDisease ProgressionCardiologyRhythm controlFemaleCardiology and Cardiovascular MedicinebusinessElectrocardiographyHumanEuropean Heart Journal
researchProduct